China Pharma subsidiary plans to launch dry eye treatment in Q1 of 2025 in China

China Pharma Holdings, an NYSE American-listed corporation with a fully-integrated specialty pharmaceuticals subsidiary based in China, announced that through Hainan Helpson Medical and Biotechnology, a wholly owned subsidiary, it expects to launch its Dry Eye Disease Therapeutic Device in the Q1 of 2025 in China. It is a medical treatment device for dry eye disease under patent protection. The Company, through Helpson, acquired the technology at the end of 2022 and has subsequently carried out the corresponding commercialization, as well as the registration and application process of the product. It has completed production commissioning and third-party testing by now. In China, the incidence of dry eye disease is about 21%-30%, second only to myopia. Treatments for dry eye-related indications include two forms of secretagogues, oral and topical, which are widely recommended for first-line and second-line treatments.